Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corporation - Common Stock (NQ:TWST)

32.78 +0.03 (+0.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Twist Bioscience Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ: 
Via Benzinga
Twist Bioscience to Present at Upcoming Investor Conferences
From Twist Bioscience Corporation
Via Business Wire
Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move. 
Via Talk Markets
7 Stocks Cathie Wood Is Still Loading Up On in Q1
You won't find many timid bets among the Cathie Wood stocks she believes will dramatically alter our future. 
Via InvestorPlace
4 Analysts Have This To Say About Twist Bioscience
Via Benzinga
Twist Bioscience Earnings Preview
Via Benzinga
7 Sexy Stocks That Will Continue to Outperform in 2024
These outperforming stocks are prime candidates for increasing in value sharply this year and beyond. Discover the top picks. 
Via InvestorPlace
Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss
Via Benzinga
Cathie Wood's Ark Invest Sheds $2.8M Worth Of Nvidia Shares Amid AI Hype, Picks Up Robinhood Stock Worth $1.3M
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT
From Twist Bioscience Corporation
Via Business Wire
Why Is DNA Synthesis Company Twist Bioscience Stock Trading Higher Today?
Twist Bioscience reported Q1 2024 earnings, beating revenue guidance and increasing FY24 guidance. Shares are up 7.16%. 
Via Benzinga
Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Earnings Scheduled For February 2, 2024
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion. 
Via Benzinga
Twist Bioscience Corp Daily Investment Opportunity
Twist Bioscience is a public biotechnology company founded in 2013 and it’s based in South San Francisco. It manufactures synthetic DNA and DNA products for customers in a wide range of industries. 
Via Talk Markets
Twist Bioscience Expands Express Genes Rapid Synthesis Service
From Twist Bioscience Corporation
Via Business Wire
Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion
Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing... 
Via Benzinga
Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Twist Bioscience to Report Fiscal 2024 First Quarter Financial Results on Friday, February 2, 2024
From Twist Bioscience Corporation
Via Business Wire
Biotech Playbook: Small Caps Show Momentum Peaking During
The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market. 
Via Talk Markets
Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Appoints Adam Laponis as Chief Financial Officer
From Twist Bioscience Corporation
Via Business Wire
3 Genomics Stocks to Unlock the Future of Medicine
Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use. 
Via InvestorPlace
Exposures Product Safety
Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Tuesday Talk: CPI Data And FOMC Meeting Hold Back Market Breakout
While the market continues towards making new highs, it is falling short of making a breakout rally. Forthcoming CPI data and the upcoming FOMC meeting may be the catalyst for same. 
Via Talk Markets
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
Five Best Performing Stocks Of The Top ETF Of November
Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way. 
Via Talk Markets
Topics ETFs
Cramer Says No To This EV Maker, But Recommends This Major Automaker Stock: It 'Goes Up And Up'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said no to Lucid Group, Inc. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.